222110 — Pangen Biotech Income Statement
0.000.00%
Last trade - 00:00- KR₩77bn
- KR₩65bn
- KR₩15bn
Annual income statement for Pangen Biotech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6,191 | 7,936 | 6,501 | 7,315 | 14,673 |
| Cost of Revenue | |||||
| Gross Profit | 1,373 | 530 | 660 | 986 | 5,150 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9,891 | 11,224 | 11,099 | 11,541 | 13,627 |
| Operating Profit | -3,699 | -3,288 | -4,598 | -4,225 | 1,046 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4,356 | -3,250 | -4,435 | -4,441 | 1,004 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4,356 | -3,310 | -4,494 | -4,489 | 944 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4,356 | -3,310 | -4,494 | -4,489 | 944 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4,356 | -3,310 | -4,494 | -4,489 | 944 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -452 | -324 | -420 | -421 | 79.2 |
| Dividends per Share |